Sugammadex: Effect on the Awareness Monitoring and Hemodynamics
NCT ID: NCT01301261
Last Updated: 2012-06-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
60 participants
INTERVENTIONAL
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Sugammadex Versus Usual Care on Incidence of Residual Blockade at Post Anesthesia Care Unit Admission (P07981)
NCT01479764
Study to Determine if Administration of Sugammadex Impacts Hospital Efficiency
NCT02860507
Comparison of Sugammadex and Sugammadex-neostigmine Combination in the Antagonism of Moderate Neuromuscular Block
NCT05228223
"Low Dose Sugammadex Combined With Neostigmine and Glycopyrrolate Versus Full Dose Sugammadex for Reversal of Rocuronium-induced Neuromuscular Blockade: a Cost Saving Strategy"
NCT02375217
Sugammadex Given for the Reversal of Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants
NCT02708056
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Group 1 receives 2 mg/kg of sugammadex when a count of two of the train of four appears Group 2 receives 4 mg/kg of sugammadex when a posttetanic count 1-3 appears Group 3 receives 16 mg/kg of sugammadex three minutes after administration of cis-atracurium.
Heart rate, arterial blood pressure, oxygen saturation, end-tidal CO2, entropy and bispectral index are recorded every three minutes
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
sugammadex 2 mg/kg
2 mg/kg of sugammadex are given when a response of two counts of train of four are present
sugammadex
Sugammadex 2 mg/kg when a two count of train of four appears
4 mg/kg of sugammadex
4 mg/kg of sugammadex are given when a posttetanic count 1-3 appears
Sugammadex 4 mg/kg
Sugammadex 4 mg/kg are given when a posttetanic count 1-3 appears
Sugammadex 16 mg/kg
Sugammadex 16 mg/kg are given three minutes after the injection of cis-atracurium
Sugammadex 16mg/kg
Sugammadex 16 mg/kg three minutes after the injection of cis-atracurium
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
sugammadex
Sugammadex 2 mg/kg when a two count of train of four appears
Sugammadex 4 mg/kg
Sugammadex 4 mg/kg are given when a posttetanic count 1-3 appears
Sugammadex 16mg/kg
Sugammadex 16 mg/kg three minutes after the injection of cis-atracurium
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* both sexes
Exclusion Criteria
* treated with antihypertensive drugs
30 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Athens
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Argyro Fassoulaki
MD, PhD, DEAA
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Anesthesiology, Aretaieio Hospital
Athens, , Greece
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Konstantinos Chondrogiannis, MD
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Argyro Fassoulaki, MD, PhD, DEAA
Role: primary
Konstantinos Chondrogiannis
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Σ-150/03-08-10
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.